Anavex Life Sciences Corporation (AVXL) オプション

Related to provisional activity originating 23-11-2021?

This application claims the benefit of U.S. Provisional Patent Application No. 63/282,615, filed on Nov. 23, 2021, and U.S. Provisional Patent Application No. 63/393,573, filed on Jul. 29, 2022, the entire disclosures of which are incorporated herein by reference.

Current list of all 27 European Union countries

https://www.countries-ofthe-world.com/european-union-countries.html

As I see it: It is a method to quickly test the effectiveness of a drug by comparing the state of gene activity before and after the drug's application. So, if a gene that when on is indicative of progression towards a disease such as Alzheimer's is present before drug treatment, but it not present, or present at reduced levels after drug treatment, then it can be inferred that the drug is having a beneficial effect. This is important for slow moving diseases such as those involving the CNS.

The patent discloses the framework of the method. It seems general enough to be a broad patent, which is desirable assuming it is granted.

I urge share owners to consider that EMA may not respond as one body for approvals (like FDA). Each EU nation has it's own regulatory process which can/may result in scattered approvals (not unanimous, not same timing or other use conditions. It's what they do.

After-Hours Consolidated Last Trade $8.5008 +0.0308 (+0.36%)
After-Hours Volume 154,737
After-Hours High $8.76 (04:24:43 PM)
After-Hours Low $8.5 (05:47:49 PM)

https://www.nasdaq.com/market-activity/stocks/avxl/after-hours

hnbadger-" don't sell anytime soon P"--are you expecting news to soon be coming ?? what kind ???? TIA

What exactly are we attempting to patent?

The abstract of the patent application titled
"Therapy Selection and Treatment of Neurodegenerative Disorders" describes a method for individualized therapy selection and monitoring for neurodegenerative disorders. The focus is on using Sigma-1 receptor agonist therapy to treat neurodegenerative diseases. The therapy is tailored based on gene expression analysis before and after treatment, enabling a personalized approach.
Additionally, the disclosure includes tools for assessing the current status or risk of a subject for developing such disorders. These tools are organized as kits that assist in implementing the described methods.

The provided document outlines the components of the kit for individualized therapy selection and monitoring for neurodegenerative disorders.
Kit Components:
1. Biological Sample Collection Materials:
• Tools for collecting biological samples, such as blood, saliva, or tissue, for analysis of gene expression.
2. Diagnostic Assays:
• Tests designed to identify biomarkers indicative of neurodegenerative disorders.
• Likely includes reagents, substrates, and controls for reliable measurement.
3. Sigma-1 Receptor Agonist:
• The therapeutic agent used in the treatment, specifically targeting Sigma-1 receptors.
• May be provided in pre-measured doses tailored to individual therapy.
4. Gene Expression Analysis Tools:
• Equipment and reagents for analyzing gene expression pre- and post-treatment.
• Could include tools for RNA sequencing or other genomic technologies.
5. Data Processing Software:
• Programs or access to cloud-based tools for interpreting genetic data.
• Algorithms to recommend individualized treatment plans based on gene expression changes.
6. Instructional Documentation:
• Guidelines for using the kit, including sample collection, therapy administration, and result interpretation.
• Step-by-step protocols to ensure consistency and reliability.
7. Risk Assessment Tools:
• Instruments or methodologies to evaluate the subject's current risk of developing neurodegenerative disorders.
• May include scoring systems or diagnostic algorithms.
Purpose and Utility
The kit is intended to:
• Provide a comprehensive platform for personalized diagnosis and therapy.
• Enable clinicians to monitor treatment effectiveness through pre-and post-treatment biomarkers.
• Facilitate early detection and preventive measures for neurodegenerative diseases.
Thanks 45bulls on stock twits!

It seems like Anavex has built a proprietary software and diagnostic toolkit for CNS diseases using blarcamesine. They give a patient drug and measure before/after genetic response. They can then diagnose or determine risk for developing CNS diseases.
PERSONALIZED MEDICINE for most CNS diseases. Congrats to all longs, don't sell anytime soon P
ppubs.uspto.gov/dirsearch-p...

That 2,347,246 looks to be the total vol for the trading day excluding AH trades.

I show total vol including AH trades as 2,514,195.

This patent application filed 23.11.2022 concerns the findings from below poster presentation at AAIC October 9-12, 2022.

Those dates is a bit of an issues as the invention was disclosed at AAIC before the patent filing date.

It is yet another way to patch up the IP protection of A2-73 standalone originally patented by Vamvakides and now expired.

US20240417798 - THERAPY SELECTION AND TREATMENT OF NEURODEGENERATIVE DISORDERS

https://patentscope.wipo.int/search/en/detail.jsf?docId=US444400063&_cid=P10-M4XSG4-93338-1

Good luck and GOD bless and have a very merry CHRISTmas.

“In press”
The publication is announcing the article has been reviewed and is accepted for publication.

As I advised last week, there was zero chance that the imaginary mm manipulators would allow the call options at $9 and above to be ITM. 

There are no more weeklies, for whatever reason, so you have another month.

A MUST READ A brand new US Patent Application

https://ppubs.uspto.gov/dirsearch-public/print/downloadBasicPdf/20240417798?requestToken=eyJzdWIiOiI4OGY5NWYxZS1hZTRkLTQ3YzUtYWRjOS01ZDgwZDNhMzE5NGEiLCJ2ZXIiOiI2YTgwZWM2YS1kYjA1LTQ1MzYtODJlZi02M2IxZGU2NjhkZDEiLCJleHAiOjB9

Good luck and GOD bless,

Triple witching day, nothing special about this POS.

Notice the MOC today 1,226,230 shares. Yes we see 60K, 100K, 160K for MOC order is not unusual. But 1,226,230 is a serious buy. Probably took all day for the MM's to bag up enough shares to cover that buy. And then later in after hours almost 19:00 2,347,246 share trade.
Click the link below and then slide across and watch the Volume By the Minute.
https://www.cnbc.com/quotes/AVXL?qsearchterm=
John k9uwa

Just ask Kund. He'll tell you. He was a huge SAVA supporter.

I agree. Sava would be at $250.00 per share right now if it had the same results as Anavex to date.. Around a $20 Billion MC. Motley Fool would have them as a Strong Buy.

All we need is one approval and is on like DK.

It is only 29 times current value. Can anyone see a problem with that?

The market cap is $700 million—who would pay $20 billion when the company can be bought for under a billion? The kick-the-can strategist is focused on maximizing his return and isn't in a hurry to get the drug to market. The EMA filing is just another gimmick from him, knowing it will take years to get any decision from the EMA.

Way low particularly taking into account they also have a credible shot at a number of additional very high value target diseases.

G, I believe a 20 billion buyout is not out of the question. However, I also think that 20b is a low ball offer for Anavex. 

Like clockwork the nearly daily downturn in the stock price of AVXL is nearly complete at about 3:00 PM EST.

This very well could of been the case with our PPS even with an announcement of EMA acceptance of our MAA application. If you believe anything else your just fooling yourself, maybe 1 or 2 others, and setting up many for disappointment. Is that your goal, reverse psychology on new longs to drive them crazy thus selling and leaving from daily undiverable expectations unmet ?

Looks like you once again got it wrong!!!

If we look at simple chart picture of a range pattern, from 7.30 bottom zone to 10.30 top zone, in the middle is 8.80 balance.8.75 resistance capped today, and also using slightly different price steps, 7.50 to the resistance shoulder zone 9.50 area, the balance middle is right here around 8.50.... the price action is ending the week settled in this neutral middle zone waiting for next week. The down move set up now is a 1 dollar wave downward to target 7.70 area/ 7.60 ...IF
It falls down next week. But if it jumps instead in a rally from here.... 1 dollar, back to retest the 9.60 and maybe 10.30, a 2 dollar move from 8.30.
If good news is the trigger, it would begin the new cycle upward... and I'd be looking first at targets like 12/13/14/15 automatic, before dreaming of any higher, like the 20's.
But for next week, simply looking for the next 1 dollar movement. 7.65 or 9.65 🎱🫣

Like clockwork the nearly daily downturn in the stock price of AVXL is nearly complete at about 3:00 PM EST. Do NOT allow the bashers, FUDsters and/or shorters paint the tape prior to the close; make them pay UP; start the SHORT SQEEZE today prior to Monday’s NEWS!!!

Good luck and GOD bless and have a very merry CHRISTmas!!!

SAVA is outperforming this dogschitt today. One thing is certain - the shorts are very confident that there will be no news of consequence on Monday. Deep down I think most longs know that too.

With all the PR since mid 2024, there is still no real progress with this POS. Misleading still milking 2 year old data. He might be getting his new option grants for another unsuccessful year.

I have to admit I'm somewhat disappointed in today's stock price I mean the xbi is up nicely and the markets are flying and here we sit dealing with pennies I was hoping to see a lot more today especially with the anticipation that some have for Monday

It might well be. Only time will tell.

Is this not going to be Feb'ish?

Stink Bid time. got few at 8.33 SOLD at 8.70. Put in new stink bid.

John k9uwa

Just FYI. as image that others have done detective work on.

That is a reasonable approach. Less risk/less reward.

If history is a guide there will be a big move up on approval and then a beat down by the mysterious forces on the market.
There may not be a beat down if approval is followed up by additional news.

I certainly thought that Rett was going to be approved and we saw how that turned out. My opinion is that AD will be approved. See the previous sentence.

It might have taken an incorrect figure, I don't think there is an IF calculated yet for 2024.

I asked google "JPAD 2024 impact factor"

Authoritarian personality types legitimately cannot handle uncertainty, and that's reflected in some posts. It really stresses them.

He's a BIO checker that, for the last 7 years, has ONLY been concerned with ONE bio - Anavex.

Well maybe you could explain the thinking behind BIOChecker and what's the with "4". I assume you consider some reference standard for the checking you do of things bio?

Regardless of which journal prints the paper, one thing is that reviewing and writing a peer reviewed paper for the next safe and effective SOC for Alzheimer’s will definitely give that journal a serious “bump”, imo.

Well said. The tactics deployed through the super complicated programming of algorithms assisted by AI is mind boggling. We see just “the tip of the iceberg” of what is being applied.

I rely on HIS time, not mine.

Your screen name is investor2014. Why don’t you explain why you chose “investor” instead of daytrader2014 or speculator2014?

Or ppl would just wait till early Jan when most late Dec EMA start dates (which avxl would be) are Pr'ed?


NOOoo, not ME! Ive waited too long and if its not announced by, by,…..by today dammit I will find the tallest building, light my hair on fire, run and jump off! (Sarc)

Why are so many continuing to hyperventilate over the stock price at every event or non event. We are very close, I really dont understand it and feel it is unnecessary self gratification by worry warts. Just the opposite of “NEWS TOMORROW!”. May one is feeding the other?

#Cutthemanicfoodsupply

Merry Christmas

I look at various situations and state my opinions based on my experience, observations, and intuition. I’m quite prepared to be wrong but so far all the evidence I’ve seen leads me to remain skeptical. I was wrong about Anavex not filing the EMA this year and as you know I offered my congratulations on that accomplishment.

I’m sorry if not bowing to the approved WGT narrative irritates you but that’s your problem, not mine. Like I’ve said, I’ll gladly pay up if blarcamesine gets approved.

"2024 impact factor for JPAD is 9.2 - that is very good."

Interesting, where did you find that? I think 8.6 is the latest IF that is known according to the journal website.

It seems like JPAD has been increasing each year whereas 'AD & Dementia' falling slightly and 'Journal of AD' not moved much.

How do you define "versus actual investors"?

Supposedly, 2024 impact factor for JPAD is 9.2 - that is very good.

The only thing I’m convinced of is that the outcome is unknowable. That’s why I’ll be perfectly happy to pay up on approval, should it happen. Unless and until that happens, AVXL remains a speculative play with significant risks better suited to speculators and day traders versus actual investors.